Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16702351 | 0.84 | KMT2A (0.49) | ALDH1A1HPGDRAB9AMEN1KMT2A | |
| SCHEMBL16709808 | 0.83 | ALDH1A1 (0.69) | ALDH1A1HPGDRAB9AMEN1KMT2A | |
| SCHEMBL19910360 | 0.80 | KMT2A (0.52) | ALDH1A1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL16709786 | 0.77 | L3MBTL1 (0.50) | ALDH1A1HPGDRAB9AMEN1KMT2A | |
| SCHEMBL24799100 | 0.77 | ANO1 (0.67) | ALDH1A1HPGDRAB9AMEN1KMT2A | |
| SCHEMBL31306535 | 0.76 | SMN1; SMN2 (0.71) | ALDH1A1HPGDRAB9AMEN1KMT2A | |
| SCHEMBL21198034 | 0.76 | SMN1; SMN2 (0.71) | ALDH1A1HPGDRAB9AMEN1KMT2A | |
| SCHEMBL28019937 | 0.76 | KCNJ5 (0.67) | ALDH1A1HPGDRAB9AMEN1KMT2A | |
| SCHEMBL9030520 | 0.74 | L3MBTL1 (0.68) | ALDH1A1HPGDRAB9AMEN1KMT2A | |
| SCHEMBL4304231 | 0.74 | ALDH1A1 (0.59) | ALDH1A1HPGDRAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253534-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2021-06-01 | — | — | US | disclosed |
| US-20200247757-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2020-08-06 | — | — | US | disclosed |
| US-10683271-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2020-06-16 | — | — | US | disclosed |
| EP-3065738-B1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| US-20170275256-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-09-28 | — | — | US | disclosed |
| US-9682939-B2 | Compositions and methods for modulating farnesoid X receptors | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-20160340317-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2016-11-24 | — | — | US | disclosed |
| WO-2015069666-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021446-B2 | Compositions and methods for modulating farnesoid X receptors | NR1H4, GPBAR1, SLC10A1 | ALDH1A1 2796/4885HPGD 1004/4885RAB9A 1731/4885 |
| US-20210253534-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | ALDH1A1 2796/4885HPGD 1004/4885RAB9A 1731/4885 |
| US-20200247757-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | ALDH1A1 2796/4885HPGD 1004/4885RAB9A 1731/4885 |
| US-20160340317-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | ALDH1A1 2796/4885HPGD 1004/4885RAB9A 1731/4885 |
| US-20170275256-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, GPBAR1, SLC10A1 | ALDH1A1 2796/4885HPGD 1004/4885RAB9A 1731/4885 |
| US-10683271-B2 | Compositions and methods for modulating farnesoid X receptors | NR1H4, GPBAR1, SLC10A1 | ALDH1A1 2796/4885HPGD 1004/4885RAB9A 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.